Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study on Patients With Hepatocellular Carcinoma (HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04021056
Recruitment Status : Recruiting
First Posted : July 16, 2019
Last Update Posted : July 16, 2019
Sponsor:
Information provided by (Responsible Party):
Jinlin Hou, Nanfang Hospital of Southern Medical University

Brief Summary:
This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.

Condition or disease Intervention/treatment
Hepatocellular Carcinoma Other: No intervention

Layout table for study information
Study Type : Observational
Estimated Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Observational Study on Patients With Hepatocellular Carcinoma (HCC)
Actual Study Start Date : January 1, 2011
Estimated Primary Completion Date : August 31, 2019
Estimated Study Completion Date : December 31, 2022



Primary Outcome Measures :
  1. Evaluate the overall survival rate of all HCC patients [ Time Frame: 10 years ]
    In order to identify the potential influence factors of HCC patients survival

  2. Evaluate the recurrence free survival rate of HCC patients after curative treatments [ Time Frame: 10 years ]
    In order to identify the potential influence factors of tumor recurrence



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed and treated as HCC in Liver Cancer Center, Nanfang Hospital
Criteria

Inclusion Criteria:

  • Clinical diagnosis of HCC;
  • Age ≥ 16 years;
  • Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
  • Good compliance with clinical treatment.

Exclusion Criteria:

  • Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
  • Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
  • HCC diagnosed after liver transplantation;
  • Poor compliance or important data deficient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04021056


Contacts
Layout table for location contacts
Contact: Jinlin Hou jlhousmu@163.com

Locations
Layout table for location information
China, Guangdong
Nanfang Hospital Recruiting
Guangzhou, Guangdong, China
Contact: Jinlin Hou       jlhousmu@163.com   
Sponsors and Collaborators
Nanfang Hospital of Southern Medical University

Layout table for additonal information
Responsible Party: Jinlin Hou, Professor, Nanfang Hospital of Southern Medical University
ClinicalTrials.gov Identifier: NCT04021056     History of Changes
Other Study ID Numbers: NFHCC-01
First Posted: July 16, 2019    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases